Literature DB >> 28558366

Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study.

Margherita Barbuti1, Isabella Pacchiarotti2, Eduard Vieta2, Jean-Michel Azorin3, Jules Angst4, Charles L Bowden5, Sergey Mosolov6, Allan H Young7, Giulio Perugi8.   

Abstract

BACKGROUND: The issue of antidepressant-induced mood switches to hypomania, mania, or mixed states within the course of mayor depressive disorder (MDD) has been a controversial topic. The present post-hoc analysis of the BRIDGE-II-MIX study focuses on the clinical features of patients with history of antidepressant-induced hypomania/mania (AIHM) in a large international sample of patients with major depressive episode (MDE).
METHODS: 2811 subjects with major depression were enrolled in this multicentre cross-sectional study. Current mixed symptoms, socio-demographic and other clinical variables were collected and compared among MDD-AIHM, MDD and BD patients.
RESULTS: 475 patients out of 2811 had history of AIHM (16.90%). In the MDD-AIHM group, familiarity for BD and rates of atypical features and comorbid anxiety, eating and borderline personality disorders were similar to BD and significantly more frequent compared to MDD group. MDD-AIHM patients had more frequently more than 3 episodes and reported higher rates of treatment resistance, mood lability and irritability following treatment with antidepressants. Frequencies of depression with mixed features and (hypo)manic symptoms were similar in patients of MDD-AIHM and BD groups and significantly higher in both groups than in MDD. LIMITATIONS: there were widely varying rates of hospitalized patients across countries and the participating centres were not randomly selected.
CONCLUSIONS: Our results strongly support the DSM-5 inclusion of MDD patients with AIHM within the rubric of bipolar disorder. Differences with other MDD and BD were also observed suggesting the possibility that MDD-AIHM may represent a specific sub-population, particularly sensitive to exogenous input from antidepressants.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28558366     DOI: 10.1016/j.jad.2017.05.035

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  12 in total

1.  Bipolar II Disorder: Frequent, Valid, and Reliable.

Authors:  Eduard Vieta
Journal:  Can J Psychiatry       Date:  2019-08       Impact factor: 4.356

2.  Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder.

Authors:  Takeshi Inoue; Toshifumi Kimura; Yoshifumi Inagaki; Osamu Shirakawa
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-12       Impact factor: 2.570

Review 3.  Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention.

Authors:  Erica Bell; Phil Boyce; Richard J Porter; Richard A Bryant; Gin S Malhi
Journal:  CNS Drugs       Date:  2021-05-21       Impact factor: 5.749

4.  Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study.

Authors:  Filippo Corponi; Gerard Anmella; Isabella Pacchiarotti; Ludovic Samalin; Norma Verdolini; Dina Popovic; Jean-Michel Azorin; Jules Angst; Charles L Bowden; Sergey Mosolov; Allan H Young; Giulio Perugi; Eduard Vieta; Andrea Murru
Journal:  Transl Psychiatry       Date:  2020-07-19       Impact factor: 6.222

5.  Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States.

Authors:  Sergey Mosolov; Christoph Born; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-06-15       Impact factor: 2.430

6.  Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials.

Authors:  Trisha Suppes; Jonas Eberhard; Ole Lemming; Allan H Young; Roger S McIntyre
Journal:  Int J Bipolar Disord       Date:  2017-11-06

Review 7.  A Review of Asenapine in the Treatment of Bipolar Disorder.

Authors:  Eduard Vieta; José Manuel Montes
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

8.  Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.

Authors:  Yasunari Yamaguchi; Sohei Kimoto; Takeshi Nagahama; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-17       Impact factor: 2.570

9.  Mania Associated With Herbal Medicines, Other Than Cannabis: A Systematic Review and Quality Assessment of Case Reports.

Authors:  Emmanuelle Bostock; Kenneth Kirkby; Michael Garry; Bruce Taylor; Jason A Hawrelak
Journal:  Front Psychiatry       Date:  2018-07-06       Impact factor: 4.157

Review 10.  Bipolar depression: a major unsolved challenge.

Authors:  Ross J Baldessarini; Gustavo H Vázquez; Leonardo Tondo
Journal:  Int J Bipolar Disord       Date:  2020-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.